Figure 5.

Knockdown of either YAP or TAZ or use of TEAD auto-palmitoylation inhibitors inhibits human schwannoma cell proliferation. (A–G) Lentiviral knockdown of either YAP or TAZ significantly reduces proliferation of human NF2-null schwannoma cells. (A–C) Representative images of EdU-positive cells, counterstained with Hoechst (Ho) from scrambled control (Scr, A), YAP knockdown (shYAP, B) and TAZ knockdown (shTAZ, C). (D) Quantification of percentage positive EdU cells for each condition. (E–G) Western blot (E) and quantification (F and G) confirming YAP or TAZ knockdown in cells; note that knockdown of TAZ does not significantly affect levels of YAP (F), but knockdown of YAP does significantly lower levels of TAZ (G). (H–K) TEAD auto-palmitoylation inhibitor (VT3) decreases human schwannoma cell proliferation in a dose-dependent manner. (L) Expression of four TEAD isoforms (TEAD1–4) in cells from three human schwannoma tumours S₁, S₂ and S₃ treated with either vehicle (left) or 2 μm VT3 for 7 days (VT, right). (M) Quantification of schwannoma cell proliferation with increasing concentrations of auto-palmitoylation inhibitor VT3. N = 3 for all data shown. Data presented in graphs are means ± SEM. Data analysis in D was one-way ANOVA with Bonferroni’s correction, in F and G matched one-way ANOVAs with the Geisser–Greenhouse correction and Tukey’s multiple comparisons test and M one-way ANOVA with Bonferroni’s correction. *P < 0.05; **P < 0.01; ***P < 0.001. Scale bars = 25 μm.